Streetbeat News

Stock Prices

REPL

Replimune Group, Inc. (NASDAQ: REPL) presented promising clinical data from its RP1 and RP2 programs at the 2024 ASCO Annual Meeting. The 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma showed an overall response rate of 32.7%. Additionally, RP2 as monotherapy and in combination with nivolumab in uveal melanoma demonstrated an overall response rate of nearly 30%.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:26 pm

NKGN

NKGen Biotech will present updated Phase 1 data of its SNK02 allogeneic NK cell therapy in solid tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:26 pm

BRK

JPM

MSFT

NVDA

Nvidia Corp (NASDAQ:NVDA) experienced a significant market cap increase of $350 billion due to a gamma squeeze, driven by a surge in call options. The company's market cap reached $2.69 trillion, surpassing JPMorgan Chase & Co (NYSE:JPM) and Berkshire Hathaway Inc (NYSE:BRK). Nvidia's Q1 earnings report and its role in generative AI were key catalysts. The event highlights both opportunities and risks for investors.

Portfolio Pulse from Surbhi Jain

June 03, 2024 | 12:26 pm

BDRX

Biodexa Pharmaceuticals reported positive Phase 2 data results for its drug eRapa, showing a 24% reduction in total polyp burden and an 83% non-progression rate, indicating high efficacy in preventing polyp growth.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:23 pm

ME

23andMe Holding Co. (NASDAQ:ME) presented positive preliminary Phase 2 safety and efficacy data for its anti-CD200R1 antibody, 23ME-00610, at the 2024 ASCO Annual Meeting. The data showed clinical benefits, including a confirmed partial response, and acceptable safety and tolerability.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:22 pm

HPE

Hewlett Packard Enterprise (NYSE:HPE) is set to release its Q2 earnings, with analysts expecting a drop in EPS from 52 cents to 39 cents and projected revenue of $6.82 billion. The company offers a 2.95% annual dividend yield, translating to 13 cents per share quarterly. Investors need approximately $203,646 in HPE stock to earn $500 monthly from dividends. HPE shares recently fell 4.7% to $17.65.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 12:21 pm

MTEM

Molecular Templates provided an update on its clinical-stage programs, highlighting continued monotherapy activity in solid tumors with MT-6402 and potential of MT-0169 in severe immune-mediated diseases.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:19 pm

TNXP

Tonix Pharmaceuticals presented new data on Tonmya, showing its potential to improve fibromyalgia-associated depression severity. The data was presented at the ASCP Annual Meeting, and the company plans to submit a New Drug Application to the FDA in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:19 pm

COYA

Coya Therapeutics' peer-reviewed manuscript on a Phase 1 proof-of-concept study evaluating the safety, tolerability, and biological marker responses of a combination therapy for Amyotrophic Lateral Sclerosis (ALS) has been accepted in the medical journal Frontiers in Neurology.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:18 pm

GRYP

Gryphon Digital Mining (NASDAQ:GRYP) will join the Russell Microcap Index, effective at the open of markets on Monday, July 1st. The company is known for its 100% renewable bitcoin mining operations and negative carbon strategy.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:17 pm